NEW YORK, March 7, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Medtronic, Inc. (NYSE:MDT), Edwards Lifesciences Corp (NYSE:EW), Cyberonics, Inc. (NASDAQ:CYBX), HeartWare International Inc (NASDAQ:HTWR) and Luxottica Group SpA (NYSE:LUX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Medtronic, Inc. Research Report
Medtronic was awarded a CE (Conformité Européenne) for its Engager Transcatheter Aortic Valve Implantation System, a valve with transapical delivery catheter that supports aortic stenosis treatment in patients who are at high or acute risk for surgical aortic valve replacement. The valve, made of bovine tissue leaflets and a self-expanding nitinol frame, is expected to be released in Europe in the second half of 2013. However, there is still no date for a US release. With this product, together with the rest of its expansion efforts of its portfolio, could rake in at least $200 million in fiscal 2014. The structural heart business has become a popular franchise in emerging markets, especially China, with the company's competitors also making strides in the business. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/b91b_MDT]
Edwards Lifesciences Corp Research Report
Edwards Lifesciences reported Q4 2012 earnings per share of 77 cents, up 45.3 percent year over year from 53 cents, and a 18.7 percent year over year increase in revenue at $510.5 million, which was within the company's guidance range. Growth was led by commercialization of the Sapien technology in the domestic market and robust performance across all operating platforms. In comparison, analysts expected 65 cents of earnings per share and revenue of $499 million. For the current quarter, revenue is expected to come at $505 to $530 million and earnings per share of 74 to 78 cents. Edwards expects full year 2013 revenue in the range of $2.1 to $2.2 billion and adjusted earnings per share in the band of $3.21 and $3.31. The Full Research Report on Edwards Lifesciences Corp - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/dbf4_EW]
Cyberonics, Inc. Research Report
Medical device maker Cyberonics reported net income growth of 39 percent in fiscal Q3 of 2012 after selling more of its nerve stimulation devices, and increased its outlook for the rest of 2013. The company netted $13.2 million in net income or 47 cents per share, up from $9.5 million or 34 cents per share. Revenue came in at $62.7 million, up 15 percent from $54.5 million. In comparison, analysts expected a profit of 38 cents per share and $60.6 million in revenue. For this fiscal year, Cyberonics now expects profit of $1.66 to $1.72 per share, up from its previously predicted $1.56 to $1.62 per share. Revenue guidance meanwhile is up in the range of $248 million to $250 million from $246 million to $249 million. The Full Research Report on Cyberonics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/255a_CYBX]
HeartWare International Inc Research Report
Heartware, a manufacturer of heart support technology, beat expectations on revenues and exceeded expectations on earnings per share in its Q4 2012 results, credited to the commercial launch of the HeartWare Ventricular Assist System in the U.S. Revenue came in at $32.7 million, up 42 percent from $23.1 million year over year, while it posted a loss of $1.46 per share, up from the previous year's loss of $1.53. In comparison, analysts expected revenue of $29.5 million and loss of $1.65 per share. For the current quarter, the estimate for revenue is $39.6 million, with an estimated loss of $1.11 per share. The company spent $22.2 million for research and development expense in the quarter, compared to $17.9 million year over year. The increased costs are a result of continuing clinical trial costs and expenses related to the advancement of HeartWare's pipeline technologies, as well as other early research initiatives. The Full Research HeartWare International Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/f680_HTWR]
Luxottica Group SpA Research Report
Luxottica, a manufacturer of both corrective and non-corrective eyewear, exceeded analyst expectations in Q4 net profit with $113.8 million, boosted by strong sales especially in emerging markets. Analysts expected net profit of $109 million, while net profit the same period last year was $95 million. Meanwhile, revenue was at $1.3 billion, up 22.3 percent from $1.07 million year over year. The company said it will focus on southeast Asian markets, including Indonesia and Thailand, in 2013 and added that it expects double-digit growth in the premium and luxury segments this year. Management says some of Luxottica's business will expand 10 percent in 2013. Meanwhile, the company also announced an 18 increase in its cash dividend to 76 cents per share. The Full Research Report on Luxottica Group SpA - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d83e_LUX]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers